Bio Business

» cell & molecular biology, regulation and FDA

Most Recent

image: Picking Up the Pace

Picking Up the Pace

By | January 1, 2016

FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.

0 Comments

image: Battling the Bulge

Battling the Bulge

By | November 1, 2015

Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

0 Comments

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

3 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: That Loving Feeling

That Loving Feeling

By | July 1, 2014

There are no FDA-approved drugs to treat low sexual desire in women, but not for lack of trying.

1 Comment

image: Penetrating the Brain

Penetrating the Brain

By | November 1, 2013

Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.

3 Comments

image: How Safe Is Your Medicine Cabinet?

How Safe Is Your Medicine Cabinet?

By | May 1, 2013

After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.

1 Comment

image: Biology Hacklabs

Biology Hacklabs

By | March 1, 2013

Fueled by donations, sweat, and occasional dumpster diving, community laboratories for DIY biologists are cropping up around the country.

2 Comments

image: The Little Cell That Could

The Little Cell That Could

By | July 1, 2012

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

1 Comment

image: Bioterrorist Battles

Bioterrorist Battles

By | January 1, 2012

A Swiss-based firm may have a back-door way to thwart a bioterrorist attack—by fighting the flu.

9 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech